RDEA3170 Monotherapy in Subjects With Gout

Ardea Biosciences

Status and phase: Completed; Phase 2

Conditions: Gout

Treatments: Drug: RDEA3170 12.5 mg; Drug: RDEA3170 5 mg; Drug: RDEA3170 10 mg; Drug: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT01927198

RDEA3170-201

Details and patient eligibility

About

This study will assess the serum uric acid lowering effects and safety of 3 dose levels of RDEA3170 compared to placebo in subjects with gout.

Full description

This monotherapy study is the initial Phase 2 study for RDEA3170 and is designed to compare the safety and efficacy of multiple dose levels of RDEA3170 with placebo when given for up to 24 weeks to subjects with gout. The placebo control for RDEA3170 is included in this study to minimize bias in study assessments and monitoring. Further, to accomplish the goal of understanding the safety profile of RDEA3170, it is important to compare RDEA3170 monotherapy with placebo for at least 24 weeks.

Enrollment: 172 patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Subject meets the diagnosis of gout per the American Rheumatism Association Criteria for the Classification of Acute Arthritis of Primary Gout.
• Subject has a serum urate level ≥ 6.5 mg/dL and ≤ 10.0 mg/dL during the Screening Period.
• Subject has a body mass index < 40 kg/m2.

Exclusion criteria

• Subject is pregnant or breastfeeding. Subject consumes more than 14 drinks of alcohol per week (eg, 1 drink = 5 oz [150 mL] of wine, 12 oz [360 mL] of beer, or 1.5 oz [45 mL] of hard liquor).
• Subject has a history or suspicion of kidney stones.
• Subject has a history or suspicion of drug abuse within the past 5 years.
• Subject has a history of symptomatic myositis/myopathy or rhabdomyolysis.
• Subject has a known or suspected human immunodeficiency virus infection.
• Subject has a positive test for active hepatitis B or hepatitis C infection.
• Subject has a history of malignancy within the previous 5 years with the exception of non-melanoma skin cancer that has been treated with no evidence of recurrence, treated cervical dysplasia, or treated in situ Grade 1 cervical cancer.
• Subject within the last 12 months with: unstable angina, New York Heart Association class III or IV heart failure, myocardial infarction, stroke, or deep venous thrombosis; or subjects currently receiving anticoagulants.
• Subject has a QT interval corrected for heart rate according to Fridericia's formula > 450 msec during the Screening Period, confirmed by a repeat assessment.
• Subject has uncontrolled hypertension.
• Subject has an estimated creatinine clearance < 60 mL/min.
• Subject has an alkaline phosphatase > 2.0 x upper limit of normal during the Screening Period.
• Subject has active liver disease or impaired hepatic function.
• Subject is receiving chronic treatment with more than 325 mg salicylates per day.
• Subject has a medical condition that requires or may require systemic immunosuppressive (eg, chronic low-dose oral prednisone) or immunomodulatory treatment.
• Subject is unable to take colchicine for gout flare prophylaxis.
• Subject is receiving strong or moderate CYP3A inhibitors, p-glycoprotein inhibitors, or digoxin.
• Subject received any strong enzyme- inducing drug or product (eg, rifampin, rifabutin, phenytoin, phenobarbital, St. John's Wort) within 2 months prior to Day 1 or refuses to refrain from taking these medications until the end of the study.
• Subject received an investigational therapy within 30 days or 5 half-lives (whichever is longer) prior to the Screening Period.
• Subject has any other medical or psychological condition, which in the opinion of the Investigator and/or Medical Monitor, might create undue risk to the subject or interfere with the subject's ability to comply with the protocol requirements, or to complete the study.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

172 participants in 4 patient groups, including a placebo group

RDEA3170 5 mg qd

Experimental group

Description:

No titration.

Treatment:

Drug: RDEA3170 5 mg

RDEA3170 10 mg qd

Experimental group

Description:

Increase from RDEA3170 5 mg to RDEA3170 10 mg qd at Week 2.

Treatment:

Drug: RDEA3170 10 mg

RDEA3170 12.5 mg qd

Experimental group

Description:

Increase from RDEA3170 10 mg to RDEA3170 12.5 mg qd at Week 4.

Treatment:

Drug: RDEA3170 12.5 mg

Placebo

Placebo Comparator group

Description:

Placebo group

Treatment:

Drug: Placebo